Utilizza questo identificativo per citare o creare un link a questo documento: http://elea.unisa.it/xmlui/handle/10556/1477
Record completo di tutti i metadati
Campo DCValoreLingua
dc.contributor.authorPicardi, Paola-
dc.date.accessioned2014-07-09T12:57:16Z-
dc.date.available2014-07-09T12:57:16Z-
dc.date.issued2014-03-19-
dc.identifier.urihttp://hdl.handle.net/10556/1477-
dc.identifier.urihttp://dx.doi.org/10.14273/unisa-320-
dc.description2012 - 2013en_US
dc.description.abstractN6-isopentenyladenosine (iPA) is a modified adenosine characterized by an isopentenyl chain derived by dimethylallyl pyrophosphate (DMAPP), an intermediate of the metabolic pathway of mevalonate, that is known to be deregulated in cancer. iPA is an endogenous isoprenoid-derived product present in mammalian cells as a free nucleoside in the cytoplasm, or in a tRNA-bound form, displaying well established pleiotropic biological effects, including a direct anti-tumor activity against several cancers. However, the precise mechanism of action of iPA in inhibiting cancer cell proliferation remains to be clarified. In this work, we investigated whether iPA could directly interfere with the angiogenic process, fundamental to cancer growth and progression, and if the growth and proliferation of human melanoma cells, known for their highly angiogenic phenotype, could be affected by the treatment with iPA. Finally, we investigated if iPA could have an immunomodulatory role targeting directly human natural killer (NK) cells, components of innate immunity that participate in immunity against neoplastic cells, in order to provide a cooperative and multifactorial mode of action of iPA to arrest cancer growth. To evaluate the potential involvement of iPA in angiogenesis, we employed human umbilical vein endothelial cells (HUVECs) as a suitable in vitro model of angiogenesis, by evaluating the viability, proliferation, migration, invasion, tube formation, and molecular mechanisms involved. Data were corroborated in mice by using a gel plug assay. iPA dose- and time-dependently inhibited all the neoangiogenesis stages, with an IC50 of 0.98 μM. We demonstrated for the first time that iPA was monophosphorylated into iPA 5'-monophosphate (iPAMP) by adenosine kinase (ADK) inside the cells. iPAMP is the active form that inhibits angiogenesis through the direct activation of AMP-kinase (AMPK). Indeed, all effects were completely reversed by pre-treatment with 5-iodotubercidin (5-Itu), an ADK inhibitor. The isoprenoid intermediate isopentenyl pyrophosphate (IPP), which shares the isopentenyl moiety with iPA, was ineffective in the inhibition of angiogenesis, thus showing that the iPA structure is specific for the observed effects. Thus, iPA is a novel AMPK activator and could represent a useful tool for the treatment of diseases where excessive neoangiogenesis is the underlying pathology... [edited by author]en_US
dc.language.isoenen_US
dc.publisherUniversita degli studi di Salernoen_US
dc.subjectN6-Isopentenyladenosineen_US
dc.subjectAngiogenesisen_US
dc.subjectMAPKen_US
dc.titleNovel Insights into the Biological Effects of the Isoprenoid Derivative N6-Isopentenyladenosine: Involvement of the Metabolic Sensor Ampk in Angiogenesis Inhibitionen_US
dc.typeDoctoral Thesisen_US
dc.subject.miurMED/04 PATOLOGIA GENERALEen_US
dc.contributor.coordinatoreBifulco, Maurizioen_US
dc.description.cicloXII n.s.en_US
dc.contributor.tutorGazzerro, Patriziaen_US
dc.identifier.DipartimentoFarmaciaen_US
È visualizzato nelle collezioni:Fisiopatologia, diagnostica e terapia molecolare delle malattie metaboliche

File in questo documento:
File Descrizione DimensioniFormato 
tesi_P_Picardi.pdftesi di dottorato3,98 MBAdobe PDFVisualizza/apri
abstract_in_inglese_P_Picardi.pdfabstract in inglese a cura dell'autore162,87 kBAdobe PDFVisualizza/apri
abstract_in_italiano_P_Picardi.pdfabstract in italiano a cura dell'autore232,08 kBAdobe PDFVisualizza/apri


Tutti i documenti archiviati in DSpace sono protetti da copyright. Tutti i diritti riservati.